JUN and metabolic dysfunction-associated steatotic liver disease: NAFLD-HCC patients exhibit upregulated levels of OGT, which plays an oncogenic role by activating the oncogenic c-jun N-terminal kinases (JNK)/c-Jun/AP-1 and nuclear factor-kappa B (NF-κB) cascades [93].